Rubicon

[Rubicon @JustGodReigns]

@DrPatrick Exciting indeed. Well done Dr Pat. Even more excited for your plan to blow up $IBRX shorts; they themselves are a cancer that needs to be eradicated. Many people truly believe in you. You have a large following on Stocktwits. Good luck Dr Pat. We trust you have a plan 🙏

[Rubicon @JustGodReigns]

@DrPatrick Is a July announcement still forthcoming? Will be awesome if you keep to your word.

[Rubicon @JustGodReigns]

@Free4UFree4Me @DrPatrick @US_FDA So they can die while continuing treatments that don't work

[Rubicon @JustGodReigns]

@theduffhoneybee @DrPatrick You would likely add ANKTIVA to your current regimen in a combination therapy

[Rubicon @JustGodReigns]

@DrPatrick The FDA sucks ass

[Dr. Pat Soon-Shiong @DrPatrick]

So this randomized study says it all. If patients fail chemo and Keytruda then adding more Keytruda or more chemo does not extend survival… 5 months is what this randomized trials show. Patients with lung cancer who failed all standards of care deserve a chance to live longer with a high quality of life. Science matters.

https://t.co/xCqspXzmrk

[Rubicon @JustGodReigns]

@DrPatrick So glad you are taking Anktiva global. Looking forward to upcoming announcements. In July, you promised 😉

[Dr. Pat Soon-Shiong @DrPatrick]

As we feared. The world and the global leadership need to address this non-infectious pandemic called cancer. Immunotherapy and cell therapy at scale is a response that is needed. Global scale.

https://t.co/EalXc1gq4L

[Kerry Burgess @KerryBurgess]

The jokes write themselves at this point....

[Rubicon @JustGodReigns]

@CrusaderBear333 @ClinchRMCF So ur gay AI generated pic settles it then? Alrighty then 🤣

[Rubicon @JustGodReigns]

$IBRX 🙏

[Brandon Clark @Brandon_r_clark]

I am in @DrPatrick clinic and I am receiving #ANKTIVA. My PET scan from last week shows no sign of any metastasis, no growth of tumor size. And to top it all off, there is hardly any activity from the tumor. In other words… it’s dying!

I would not be alive right now had it not be for Dr Pat and #immunitybio

[Brandon Clark @Brandon_r_clark]

I am in @DrPatrick clinic and I am receiving #ANKTIVA. My PET scan from last week shows no sign of any metastasis, no growth of tumor size. And to top it all off, there is hardly any activity from the tumor. In other words… it’s dying!

I would not be alive right now had it not be for Dr Pat and #immunitybio

[Dr. Pat Soon-Shiong @DrPatrick]

The complex robot arm that is taught where and when to handle our NK cells as these cells grow in this revolutionary machine! Assembly on track. The world bank of NK cells made available to all ..global expansion in motion.

[Dr. Pat Soon-Shiong @DrPatrick]

AI DRIVEN ROBOT IN ASSEMBLY IN LOS ANGELES! This will change the speed and scale of cell therapy

[Tony Lane 🇺🇸 @TonyLaneNV]

A woman hiking in Canada nearly became a grizzly’s next meal and the video circulating right now is genuinely one of the most intense wildlife encounters you will ever watch - her dog is with her, a massive grizzly is right there, and somehow she kept her head together long enough for both of them to walk away breathing.

That is not a small thing. Most people talk tough until nature is standing ten feet in front of them and every instinct in your body is screaming to run, and running is exactly the worst thing you can do.

Grizzlies are built to chase, they top out over 700 pounds and can cover ground faster than any human alive. The people who survive these moments are the ones who override pure fear with pure discipline and this woman did exactly that.

If you hike, camp, or spend any real time in the wilderness - bear spray is not optional, it is the difference between a story you tell and one somebody else tells about you.

Could you have kept your cool?

Hats off to her.

[Piers Morgan @piersmorgan]

How can anyone still support this Israeli govt when psychopathic monsters like Ben Gvir are ministers in it, advocating genocide in Lebanon? Disgusting.

[Lori Mills @LoriMills4CA42]

Andrew and I are in Washington, D.C. today, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere.
We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight, giving hope and new options to those who need them most.
Please watch the testimony. I hope it resonates with you.
Together, we’re pushing for real progress. @bullishbruk
@DrPatrick

[Liz Wang @Lizdaretodream]

$IBRX (ImmunityBio) — As a former physician, this is one of the most undervalued oncology assets I’ve seen in years.

Countless cancer patients run out of options while their immune systems were destroyed by chemo and radiation. $IBRX is the right medicine to restore their immune system.

Proven Mechanism (FDA-Validated):
ANKTIVA is the world’s first IL-15 superagonist. It selectively activates NK cells, CD8+ killer T-cells, and CD4+ helper T-cells while generating durable memory T-cells — without stimulating suppressive Tregs. The NCI ranked IL-15 #1 as the most promising molecule for curing cancer. The science here is exceptional.

Compelling Clinical Data:
• In BCG-unresponsive NMIBC with papillary disease: 12-month DFS 58.2%, 3-year disease-specific survival 96%, and 81.8% bladder preservation at 3 years — over 80% of patients avoided radical cystectomy. Long-term data published in Journal of Urology.
• In advanced NSCLC after checkpoint failure: median OS 14–21+ months (well beyond historical controls of ~9 months), with some patients alive 4+ years later and clear immune restoration (reversing lymphopenia).
Strong data continues at ASCO 2026.

Commercial traction is real and accelerating:
Full-year 2025 net product revenue reached $113 million (+700% YoY) with 750% unit growth.
Q1 2026 delivered a record $44.2 million (+168% YoY, +15% QoQ). Sales momentum is building every single quarter.

Why it’s so undervalued:
Approved or authorized across ~34 countries (US, EU, UK, Saudi Arabia — including first lung cancer approval in Saudi).

Pipeline is advancing rapidly: sBLA for papillary NMIBC on track, BCG-naïve pivotal trial fully enrolled, NSCLC Phase 3 ongoing, plus programs in glioblastoma, pancreatic, lymphoma, and lymphopenia.
Current market cap ~$7.25B with the stock still near $7.

Analyst average target ~$14.20 (highs to $23+). With revenue scaling and label expansions, the real intrinsic value is significantly higher.

This isn’t just another biotech story — it’s a commercial-stage immunotherapy platform with 5–10x potential still trading near $7.

$IBRX ANKTIVA has the mechanism, the data, the approvals, and now the commercial ramp. Real patient demand is here and growing.

Big Pharma can’t suppress this forever. Dr. Patrick Soon-Shiong’s team is executing hard. Catalysts are lined up. $IBRX 🚀

(Former physician perspective. Not financial advice — always do your own research and DYOR!)

[Rubicon @JustGodReigns]

@DrPatrick We love you Dr. Pat. God bless you in this important work 🙏